[d-Leu-4]-OB3, a synthetic peptide amide with leptin-like activity, augments the effects of orally delivered exenatide and pramlintide acetate on energy balance and glycemic control in insulin-resistant male C57BLK/6-m db/db mice

Will, 2004, Global prevalence of diabetes, Diabetes Care, 27, 1047, 10.2337/diacare.27.5.1047 World Health Organization, 1997, Obesity: prevention and managing the global epidemic Centers for Disease Control, Prevention (CDC), 2004, Prevalence of overweight and obesity among adults with diagnosed diabetes – United States, 1988–1994 and 1999–2002, MMWR, Morb Mortal Wkly Rep, 53, 1066 Jack, 2004, Aging Americans and diabetes, Geriatrics, 59, 14 Lovejoy, 2002, The influence of dietary fats on insulin resistance, Curr Diab Rep, 2, 435, 10.1007/s11892-002-0098-y Hu, 2002, Sedentary lifestyle and risk of obesity and type 2 diabetes, Lipids, 38, 103, 10.1007/s11745-003-1038-4 Lang, 2008, Association of urinary bisphenol A concentration with medical disorders and laboratory abnormalities in adults, JAMA, 300, 1303, 10.1001/jama.300.11.1303 Lyssenko, 2008, Clinical risk factors, DNA variants, and the development of type 2 diabetes, N Engl J Med, 363, 2220, 10.1056/NEJMoa0801869 Lovejoy, 2002, The influence of dietary fat on insulin resistance, Curr Diab Rep, 2, 435, 10.1007/s11892-002-0098-y Johnson, 2012, Diabetes and cancer (1): evaluating the temporal relationship between type 2 diabetes and cancer incidence, Diabetologia, 10.1007/s00125-012-2525-1 Renehen, 2012, Diabetes and cancer (2): evaluating the impact of diabetes on mortality in patients with cancer, Diabetologia, 10.1007/s00125-012-2526-0 Lincoff, 2007, Pioglitazone and risk of cardiovascular events in patients with type 1 diabetes mellitus, JAMA, 298, 1180, 10.1001/jama.298.10.1180 Graham, 2010, Risk of acute myocardial infarction, stroke, heart failure, and death in elderly medicare patients treated with rosiglitazone or pioglitazone, JAMA, 304, 411, 10.1001/jama.2010.920 Fujita, 2011, Cytotoxicity of troglitazone through PPARγ-independent pathway and p38 MAPK pathway in renal cell carcinoma, Cancer Lett, 312, 217, 10.1016/j.canlet.2011.08.010 Derosa, 2012, Anti-obesity drugs: a review about their effects and their safety, Expert Opin Drug Saf, 11, 459, 10.1517/14740338.2012.675326 Grasso, 2011, Novel approaches to the treatment of obesity and type 2 diabetes mellitus: bioactive leptin-related synthetic peptide analogs, Recent Pat Endocr Metab Immune Drug Discov, 5, 163, 10.2174/187221411797265917 P. Grasso, D.W. Lee, M.C. Leinung. Leptin-related, peptides. US7777388 (2004), US7186694 (2007), US7208752 (2007), US7290638 (2010), Australia772278 (2004). Grasso, 1997, In vivo effects of leptin-related synthetic peptides on body weight and food intake in female ob/ob mice: localization of leptin activity to domains between amino acid residues 106 and 140, Endocrinology, 138, 1413, 10.1210/endo.138.4.5087 Grasso, 1999, Epitope mapping of secreted mouse leptin utilizing peripherally administered synthetic peptides, Regul Pept, 84, 93, 10.1016/S0167-0115(99)00082-8 Grasso, 1999, Inhibitory effects of leptin-related synthetic peptide 116–130 on food intake and body weight gain in female C57BL/6J ob/ob mice may not be mediated by peptide activation of the long isoform of the leptin receptor, Diabetes, 48, 2204, 10.2337/diabetes.48.11.2204 Rozhavskaya-Arena, 2000, Design of a synthetic leptin agonist: effects on energy balance, glucose homeostasis, and thermoregulation, Endocrinology, 141, 2501, 10.1210/endo.141.7.7556 Grasso, 2001, [D-Leu-4]-OB3, a synthetic leptin agonist, improves hyperglycemic control in C57BL/6J ob/ob mice, Regul Pept, 101, 123, 10.1016/S0167-0115(01)00274-9 Maggio, 2006, Intravail™, highly effective intranasal delivery of peptide and protein drugs, Expert Opin Drug Deliv, 3, 529, 10.1517/17425247.3.4.529 Huang, 2009, Prediction of pharmacological and xenobiotic responses to drugs based on time course gene expression profiles, PLoS One, 4, e8126, 10.1371/journal.pone.0008126 Greb, 2011, Reformulating injectables for oral delivery, Pharm Technol, 35, 48 Alkyl, 2005, (C10-C16) polyglycosides: exemptions from the requirement of a tolerance, Fed Regist, 70, 54281 Ahsan, 2001, Enhanced bioavailability of calcitonin formulated with alkylsaccharides following nasal and ocular administration in rats, Pharm Res, 18, 1742, 10.1023/A:1013330815253 Pillion, 1994, Insulin delivery in nosedrops: new formulations containing alkylglycosides, Endocrinology, 135, 2386, 10.1210/endo.135.6.7988421 Ashan, 2003, Effects of the permeability enhancers tetradecylmaltoside and dimethyl-β-17 cyclodextrin, on insulin movement across human bronchial epithelial cells, Eur J Pharm Sci, 20, 27, 10.1016/S0928-0987(03)00163-5 Arnold, 2002, Nasal administration of low molecular weight heparin, J Pharm Sci, 91, 1707, 10.1002/jps.10171 Cervera, 2008, Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes, Am J Physiol Endocrinol Metab, 294, E846, 10.1152/ajpendo.00030.2008 Nguyen, 2011, The glucose lowering potential of exendin-4 orally delivered via a pH-sensitive nanoparticle vehicle and effects on subsequent insulin secretion in vivo, Biomaterials, 22, 2673, 10.1016/j.biomaterials.2010.12.044 Ryan, 2005, Pramlintide in the treatment of type 1 and type 2 diabetes mellitus, Clin Ther, 26, 1500, 10.1016/j.clinthera.2005.10.009 Novakovic, 2010, Oral delivery of mouse [D-Leu-4]-OB3, a synthetic peptide amide with leptin-like activity, in male C57BL/6J wild-type and ob/ob mice: effects on energy balance, glycaemic control and serum osteocalcin levels, Diabetes Obes Metab, 12, 532, 10.1111/j.1463-1326.2009.01189.x Waldrop, 2010, Intranasal delivery of mouse [D-Leu-4]-OB3, a synthetic peptide amide with leptin-like activity, improves energy balance, glycaemic control, insulin sensitivity and bone formation in leptin-resistant C57BLK/6-m db/db mice, Diabetes Obes Metab, 12, 871, 10.1111/j.1463-1326.2010.01243.x Novakovic, 2009, Intranasal administration of mouse [D-Leu-4]-OB3, a synthetic peptide with leptin-like activity, enhances total uptake and bioavailability in Swiss Webster mice when compared to intraperitoneal, subcutaneous, and intramuscular delivery systems, Regul Pept, 154, 107, 10.1016/j.regpep.2009.01.002 Lee, 2010, Oral delivery of mouse [D-Leu-4]-OB3, a synthetic peptide with leptin-like activity, in male Swiss Webster mice: a study comparing the pharmacokinetics of oral delivery to intraperitoneal, subcutaneous, intramuscular, and intranasal delivery, Regul Pept, 160, 129, 10.1016/j.regpep.2009.12.008 Calve, 1996, Molecular basis and clinical application of biological markers of bone formation, Endocr Rev, 17, 338 Fecundate, 2009, Bone as an endocrine organ, Trends Endocrinol Metab, 20, 230, 10.1016/j.tem.2009.02.001 Maggio, 2011, Oral delivery of octreotide acetate in Intravail® improves uptake, half-life, and bioavailability over subcutaneous administration in male Swiss Webster mice, Regul Pept, 167, 233, 10.1016/j.regpep.2011.02.009 Roth, 2008, Leptin responsiveness restored by amyl in agonist in diet-induced obesity: evidence from nonclinical and clinical studies, Proc Natl Acad Sci U S A, 105, 7257, 10.1073/pnas.0706473105 Drivakis, 2010, Multi-hormonal weight loss combination in diet-induced obese rats: therapeutic potential of cholecystokinin?, Physiol Behav, 100, 187, 10.1016/j.physbeh.2010.02.023 Moon, 2011, Leptin and amylin act in an additive manner to activate overlapping signaling pathways in peripheral tissues, Diabetes Care, 34, 132, 10.2337/dc10-0518 Turek, 2010, Mechanisms of amylin/leptin synergy in rodent models, Endocrinology, 151, 143, 10.1210/en.2009-0546